Telix Pharmaceuticals (TLPPF) Non-Current Debt (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Non-Current Debt for 4 consecutive years, with $504.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Debt changed N/A year-over-year to $504.9 million in Q2 2026; TTM through Jun 2026 was $504.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $391.9 million, up 14.66% from the prior year.
• Non-Current Debt was $504.9 million for Q2 2026 at Telix Pharmaceuticals, up from $391.9 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $504.9 million in Q2 2026 and troughed at $5.3 million in Q4 2023.
• A 4-year average of $315.8 million and a median of $376.4 million in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt soared 6652.77% in 2024 and increased 8.6% in 2025, its largest moves.
• Over 4 years, Non-Current Debt stood at $5.3 million in 2023, then jumped by 6652.77% to $360.9 million in 2024, then increased by 8.6% to $391.9 million in 2025, then advanced by 28.82% to $504.9 million in 2026.
• The last three Non-Current Debt figures came in at $504.9 million (Q2 2026), $391.9 million (Q4 2025), and $360.9 million (Q4 2024), per Business Quant data.